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Abstract 
Menopause is a passage in every woman' s life. Hormonal changes are responsible 
for the cessation of ovulation, and this transition can be difficult for some women. 
Vasomotor symptoms (VMS), consisting of hot flashes/flushes and night sweats, can be 
bothersome for some, and VMS are the primary reason for women to seek medical 
attention during menopause. Patient-centered care (PCC) is an approach which improves 
discussion, promotes patient involvement, and creates a positive provider/patient 
relationship with a result of improved quality of life (QOL). Hormone therapy, the gold 
standard for VMS relief, has come under scrutiny in recent years due to a fear of 
increased health risks with its use. Complementary and alternative medicines are being 
promoted as natural alternatives. Women are seeking help to make sense of the variety of 
treatment options available for VMS relief and nurse practitioners are in an optimal 
position to help these women. Through the use of PCC, nurse practitioners (NP) can 
conduct a thorough health history and assessment. They can provide expert advice, hold 
di scuss ions with women about their preferences and assess them for individual risks with 
the ultimate provision of appropriate and individualized care for women experiencing 
VMS of menopause. 
lll 
TABLE OF CONTENTS 
Abstract II 
Table of Contents lll 
Acknowledgements v 
Chapter One Introduction 6 
Background and Need 7 
Population 7 
Need 8 
Menopause 8 
Estrogen 9 
Vasomotor Symptoms 10 
Quality of Life 11 
Patient-Centered Care 12 
Health Care Providers-Nurse Practitioner 13 
Treatment Options 15 
Lifestyle 16 
Hormone Therapy 16 
Complementary and Alternative Medicine 18 
Non-honnonal Therapy 20 
Chapter Two Literature Review 20 
Inclusion Criteria 21 
Exclusion Criteria 22 
Search Strategy 22 
Findings 24 
Quality of Life 25 
Patient-Centered Care 26 
Patient Participation 27 
Assessment of the Menopausal Woman 29 
Nurse Practitioner 32 
Current Treatments 34 
Lifestyle Factors 34 
Honnone Therapy 36 
Complementary and Alternative Medicine 41 
Non-hmmonal Therapy 44 
Limitation ofReview 45 
Chapter Three Discussion, Implications, Recommendations 
and Conclusion 46 
Discussion 46 
Implications for Practice 51 
Recommendations 52 
-References 
Appendix 1 
Appendix 2 
Future Research 
Conclusion 
52 
53 
55 
67 
68 
lV 
Acknowledgements 
Writing this paper has been a very long process. Its completion has taken many a 
sleepless night and a few tears of frustration. The final product could not have been 
realized without the encouragement of many special people. 
v 
First of all I would like to thank my daughter and son-in-law for their patience and 
understanding and I know they are as happy as I am to have this process finished . 
Secondly I have wonderful friends upon whom I have heavily relied. Thank you 
to my friend Nikki who took time to read my first really bad version. Natalie made me 
mad but made me think more critically about the 'so what' of this paper. Finally Lorri 
was my godsend who corrected my poor language and encouraged me to the bitter end. 
Lastly I would like to thank Lela Zimmer my lead committee member and Linda 
Van Pelt who kept asking for more and more to create a project I can be proud of and I 
cannot forget Kristi who handled my phone calls with professionalism and empathy. 
Thank you all very much 
6 
CHAPTER! 
Introduction 
Menopause is a transition in every woman's life. It occurs due to the loss of 
ovarian follicular action that results in amenorrhea where no other pathologic or 
physiologic cause is implicated (Rowe, Blake & Belisle, 2006; Weismiller, 2009). During 
the transition to menopause, and during menopause itself, the body's production of 
reproductive hormones and especially estrogen is reduced. It is the deficiency of estrogen 
that is implicated in the incidence of vasomotor symptoms (VMS) such as hot flashes and 
night sweats (Weismiller, 2009). Menopause is not a disease; it is a reproductive 
transition that will occur in every woman. Menopause may significantly affect the quality 
of life (QOL) of women and this is evident in that VMS are one ofthe primary reasons 
why women in the perimenopause and menopausal transition seek medical attention (Col, 
Guthrie, Politi & Dennerstein, 2009; Godfrey & Low Dog, 2008; Lewis, 2009; Reid, 
Blake, Abramson, Khan, Senikas & Fortier, 2009). There can be significant individual 
loss associated with VMS such as sleep disturbances and a reduced sense of well-being 
but for most women the symptoms can be effectively managed in collaboration with the 
woman and her health care provider. 
The purpose of this paper is to review current literature in order to answer the 
following question: Can nurse practitioners utilize a patient-centered care approach to 
help improve the quality of life (QOL) of women experiencing VMS? The background of 
menopause and vasomotor symptoms will be reviewed along with infonnation regarding 
a population of women in the peri menopause and menopausal period. The concept of 
patient-centred care (PCC) as implemented by the nurse practitioner (NP) will be 
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introduced as an approach to care that facilitates improved patient satisfaction and 
ultimately QOL for women experiencing VMS. A discussion of how shared decision-
making is important to women during a patient-centered health visit and how NPs can 
adopt these preferences will be discussed. Evidence-based information related to lifestyle 
and therapies for the management of VMS will be discussed. Finally implications and 
recommendations for NP practice will be made which will assist NPs in providing 
individualized symptom management and care for women experiencing VMS of 
menopause. 
Background and Need 
Population 
The population referred to in this paper is Caucasian peri-menopausal and 
menopausal women of the province of British Columbia (BC), Canada. Most women 
begin the transition to menopause at approximately age 47, typically with changes in 
length and frequency of menstrual cycles (Weismiller, 2009). In Canada, natural 
menopause is defined as 12 months of amenorrhea which occurs at an average age of 
51.2 years (Rowe et al., 2006). An age range of between 45 to 54 years has been chosen 
to reflect the perimenopausal period which lasts approximately ten years including the 
first 12 months of compete amenorrhea and on into the menopause period (Canderelli, 
Leccesse, & Miller, 2007). In BC, 16.2% of the population are women between 45 and 54 
years of age with 85% of that population being Caucasian which equates to 13.7% of the 
population in BC being Caucasian women in the menopause transition (BC Stats, 2006). 
There may be over 289,000 Caucasian women in BC who will be entering or are in the 
midst of menopause transition. Caucasian women were chosen as a reference because 
comparable studies in non-caucasian women are lacking (Cheung, Chaudhry, Kapral, 
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Jackevicius & Robinson, 2004) however; this paper will demonstrate that the use ofPCC, 
which focuses on individualized care, is applicable to all women. 
Need 
The symptoms of menopause vary for women. Menstrual irregularity is common 
in the peri-menopausal period. The amount and duration of menstrual flow changes and 
some women may experience missed or prolonged cycles (Weismiller, 2009). During the 
passage toward, and in the first few years following menopause, women may experience 
VMS such as hot flashes and night sweats. For most women, VMS are unpleasant, but for 
some, VMS can be quite bothersome. In this paper the term bothersome is meant to 
represent VMS for which women seek medical care. Studies have shown that 50% to 
88% of women in developed countries seek health care for distress related to symptoms 
of menopause (Hyde, Nee, Drennan, Butler & Howlett, 2010; Godfrey & Low Dog, 
2008; Lukes, 2008; Stubbs, Cohen & Carr, 2008). Approximately 15% to 30% of 
perimenopausal and menopausal women will consult health care providers for symptom 
relief from VMS (Politi, Schleinitz & Col, 2008). A Canadian review by Bachmann 
(2005) found this number to be higher reporting 40% to 60% of Caucasian women 
experiencing moderate to severe hot flashes, with 10% to 20% of that 60% finding VMS 
almost intolerable. 
Menopause 
There is no chronological age at which women enter or leave certain periods of 
the menopause transition (Soules, Sherman, PatTott, Rebar, Santoro, Utian eta!., 2001). 
The age for the initiation of menopause has been suggested to be approximately 40 years 
with a complete loss of production of estrogen occutTing around age 55 (Cobin, 2006). 
Peri menopause begins when the levels of estrogen and progesterone begin to fall and it 
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lasts approximately 10 years (Canderelli et al., 2007). Menopause and the transition 
towards it are frequently described and defined differently in literature, but for the 
purposes of this paper, the peri-menopausal time period is defined as the period leading 
up to and including the first 12 months after cessation of menses. Women then enter into 
menopause which is defined as 12 months after complete cessation of menses (Canderelli 
et al., 2007; Rowe et al., 2002). Menopause is a complex physiological event with many 
physical manifestations including VMS. A decline in estrogen is prevalent in this 
process; therefore a brief overview of the role that estrogen plays in this transition will be 
discussed. 
Estrogen 
Estrogens are derived from cholesterol in a complex mechanism of hormone 
synthesis. Estrogen is a broad term that encompasses the three hormones estradiol, 
estrone, and estriol (Deneris & Huether, 2006). Estradiol is the most potent and plentiful 
of the estrogens and is mainly secreted by the granulosa cells of follicles in the ovaries 
with a small amount originating in the adrenal cortex. Androgens are male honnones 
found in low levels in females, and they are converted to estrone in ovarian and 
peripheral adipose tissues. Estriol is a metabolite of estrone and estradiol. Pulsitile 
secretions of gonadotropin-releasing hormone (GnRH) occur, which in turn stimulates 
the secretion of leuteinizing hormone (LH) and follicle-stimulating honnone (FSH) from 
the anterior pituitary; thus, GnRH drives the ovarian production of estradiol. As women 
age, the number of ovarian follicles decline with the consequent loss of granulosa cell 
function (Burger, Dudley, Mamers, Robertson, Groome et al., 2002). The occurrence of 
hot flashes coincides with a decrease in estradiol secretion. Estrogen deficiency is also 
thought to place women at increased risk for vaginal atrophy, cardiovascular 
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complications and osteoporosis. Although these other symptoms exist, it is beyond the 
scope of this paper to discuss them all. The Society of Obstetricians and Gynaecologists 
of Canada (SOGC) recognize that menopause and its symptoms include more than just 
VMS and assert that women seek medical care for these other symptoms as well (Reid, et 
al., 2009); however, this paper will focus only on VMS. 
Vasomotor symptoms 
A vasomotor symptom is a term meant to represent hot flashes and night sweats. 
The terms hot flash and hot flush are often used interchangeably in the literature and for 
the purpose of this paper the term hot flash will be used. A hot flash is the sudden onset 
of a sensation of heat, accompanied by sweating and flushing that occurs in the face and 
spreads to the head, neck and chest lasting one to five minutes (Stubbs et al., 2008). The 
etiology of the hot flash is unknown, but lability is thought to occur in the 
thermoregulatory center of the hypothalamus in relation to falling estrogen and 
progesterone levels (MacLennan, Broadbent, Lester & Moore, 2004). A narrowing of the 
thermoregulatory zone occurs so that small changes in temperature can stimulate 
sweating or shivering (MacLennan et al., 2004). Estrogen effects are thought to be partly 
mediated through the serotonergic system (Weismiller, 2009). It has been hypothesized 
that serotonin and norepinephrine, two neurotransmitters in the brain, also decline 
affecting the thermoregulatory center of the hypothalamus (Nelson, Vesco, Haney, Fu, 
Nedrow, Miller et al. , 2006; Pinke1ion, Stovall & Kightlinger, 2010). The decline in these 
neurotransmitters in the hypothalamus increases a release of serotonin and 
norepinephrine which in tum lowers the thermoregulatory leve l leading to inappropriate 
heat loss mechanisms such as hot flashes (Nelson et al., 2006; Weismiller, 2009). VMS 
are symptoms that can cause great concern for women and may interfere with their QOL. 
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Quality of life 
When women are faced with bothersome hot flashes and night sweats, there can 
be a negative impact their QOL. Quality of life can be defined as an individual's belief 
about functioning and achievement (Utian, 2005). Most women manage to successfully 
navigate through their reproductive lives without revealing overt symptoms of 
menstruation; however, during the transition into menopause they often lose control over 
the ability to conceal menopausal effects (Morris & Symonds, 2004). Some women are 
not bothered by these symptoms while others are greatly disturbed by flushing, sweating, 
palpitations, and anxiety (Reid et al., 2009). Perimenopausal and menopausal VMS will 
vary and fluctuate differently among individual women. Hot flashes and night sweats can 
lead to sleep disturbances, insomnia and /or irritability. When these symptoms are 
combined with potentially emban·assing physical signs of flushing and perspiration, a 
woman's QOL may be negatively affected. 
Assessment of QOL must take into consideration somatic symptoms such as hot 
flashes and night sweats, psychological symptoms such as mood swings or anxiety and 
life circumstances such as soc ial impainnent. For example VMS that occur during 
sleeping hours can disrupt sleep resulting in insomnia or fatigue and psychological 
symptoms such as mood swings and irritability. These influence and affect women's 
general well-being when examining the need for VMS management (Bachmann, 2005; 
Uti an, 2005). Flush-related activity does contribute to the reduction of QOL and is 
exemplified by the woman peeling off layers of clothing as she looks for a window to 
open. This has the potential to lead to a feeling of embarrassment if this visible show of a 
hot flash occurs at inopportune moments such as during a business meeting or at a social 
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event. VMS contribute to noticeable signs of aging and can reduce women's self-image. 
Decreased QOL was positively correlated with moderate to severe hot flashes compared 
to women without hot flashes (Bachmann, 2005; Utian, 2005). Therefore the need to 
manage VMS of menopause is established through negative individual consequences and 
those to society as well. VMS may have detrimental societal effects particularly if a 
woman's sleep and mood are impaired. Their ability to function, for example in their 
occupation or social life, may be negatively affected (Bachmann, 2005). Utian (2005) 
finds that it is difficult to quantify QOL since there are many factors that contribute to 
overall QOL. It is therefore asserted that a positive improvement of QOL related to VMS 
would include patient satisfaction with the health care encounter and management plan 
that increases adherence to mutually agreed upon treatment options. NPs utilizing patient-
centered care in the health encounter will improve women's QOL by assisting them to 
manage their bothersome VMS. 
Patient-centered care 
To be patient-centered is to find out what patients want in regard to their pursuit 
of health care. PCC is defined different ly based on where and how it is being used, for 
example, from a policy perspective, it is a measure of healthcare quality and a means for 
tailoring treatment to meet patient needs, improve patient-provider communication and 
set patient goals based on patient preference (Robinson, Callister, Berry & Dearing, 
2008). A patient-centered approach can also emphasize the positive perspective of 
patients' well-being and involvement in care (Guimond, Bunn, O'Connor, Jacobsen, Tait, 
Drake, et al, 2003). For the purpose of this paper, PCC will be defined as taking into 
account the patient's desire for information and for shared decision-making and the 
practitioner responding appropriately (Stewart, 200 l ). The reason for use of a patient-
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centered framework is to improve patient satisfaction and for the practitioner to provide 
appropriate, safe and effective care that is based upon the patients' needs and goals. 
Understanding the patients' goals encourages shared decision-making between patient 
and provider which assists in identifying barriers and offering solutions that incorporates 
the patient perspective (Robinson et al., 2008). It does not exclude the promotion of 
evidence-based practice by the provider but patient centeredness seeks to find the best 
individualized care for the patient (Robinson et al., 2008). 
Health care providers- Nurse Practitioners 
Women present with concerns to the health care providers when they are seeking 
information and a management plan for resolution of a problem. In the province of BC, 
there are various health care providers including NPs. In BC, the first point of access 
traditionally was the general practitioner and in response to reduced access to health care, 
"NPs have been incorporated within the primary health care team to enhance the 
provision of timely, accessible, cost-effective, and quality health care for all Canadians" 
(CNA, 2006, p. 3). In BC, NPs are prepared to work independently in primary care 
settings such as clinics or community health care centers as well as where primary health 
care services might be available such as a non-urgent area of an emergency depatiment 
(CRNBC, 201 Oa). A NP is not a physician substitute. Instead they are independent 
practitioners that bring a unique approach to providing health care (Weiland, 2008). NPs 
in BC are registered nurses who have achieved graduate level education as well as 
advanced training and have met the requirements ofNP registration (CRNBC, 2010a). 
Nurse practitioners in BC practice in accordance with the College of Register Nurses of 
British Columbia's (CRNBC) standards of practice developed to distinguish specific 
aspects ofNP practice. The CRNBC provides a scope of practice document that sets 
standards, limits and conditions for NPs. The document is meant to be an evolving 
practice document whereby specialty practice is achievable after a negotiated 
preceptorship until the NP is deemed to meet competencies to work independently 
(CRNBC, 2010a). 
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In BC, there are three streams ofNP education which include family, pediatric or 
adult, and for discussion purposes the NP referred to in this paper will be the family NP. 
Along with a focus on holistic nursing, NPs possess competencies of strong knowledge 
and skills related to assessing, diagnosing, and treating acute and chronic illnesses as well 
as focusing on health promotion, treatment and management of health conditions (CNA, 
2008). A competency is integrated knowledge, skills, judgment and personal attributes 
required of nurses to practice safely and ethically in a designated role and setting (CNA, 
2008). In BC, the competencies are organized in a conceptual framework of four 
categories: 1) professional role, responsibility and accountability, 2) health assessment 
and diagnosis, 3) therapeutic management and, 4) health promotion and prevention of 
illness and injury (CRNBC, 20 1 Ob ). The competencies in each category build on 
competencies already present in the registered nurse such as advanced health assessment 
and diagnosis, and they address the unique practice role of the NP (CRNBC, 201 Ob ). 
Training in advanced health assessment is thought to be integral to practice and forms a 
solid foundation upon which all other competencies are built (Kelley, Kopac & Rosselli, 
2006). The advanced graduate education that NPs undertake provides them with 
additional knowledge and skills that assists NPs in understanding and utilizing the 
substantial amount of information surrounding menopause, its symptoms and the various 
treatment modalities (Mosconi, Donati, Colombo, Mele, Liberati, et al., 2009; Todd Pace, 
2006). 
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Studies have shown that women prefer to obtain information from their health 
care provider rather than attempting to read through the vast amount of information 
available to them (Annitage, Suter, Verhoef, Bockmuehl & Bobey, 2007). The standards 
and competencies of the NP role place NPs in an optimal position to assist in the 
management of VMS when women experiencing them are faced with a reduced QOL. 
The NP is able to meet the treatment needs of peri- and menopausal women by critically 
discussing the various treatment options from prescription to over the counter 
medications available for treatment of VMS. 
Treatment Options 
Due to the results of recent studies and the variety of touted options for treating 
VMS, it has become more difficult for women and providers alike to select appropriate 
treatments. A landmark study on HT was conducted in the late 1990's and early 2000. 
The Women's Health Initiative (WHI) study was divided into three arms of investigation 
to study specific interventions and their effects on women's health (Furniss, 2002). HT 
was one intervention in the study. The results of the WHI study has influenced treatment 
management of women in the perimenopause and menopause transition and has led to an 
under treatment of women for menopausal symptoms that has left a substantial 
population of women suffering from VMS as well as other symptoms of menopause 
(Lewis, 2009). This section will discuss some of the available types of treatment that are 
effective for the relief of VMS and will more specifically include implementing lifestyle 
changes, commencing HT, complementary alternative medicines (CAM) or non-
hormonal therapies. It has also been established that women seek help from their health 
care provider for management of VMS. It has also been discovered that the hot flash may 
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be a result of a change in the thennoregulatory system, so it would be appropriate to start 
the discussion with lifestyle choices before progressing into medication options. 
Lifestyle. 
Lifestyle changes should be considered when it comes to management of VMS 
associated with perimenopause and menopause. Reid et al. (2009) examined modifiable 
risk factors, such as smoking, abdominal obesity, diabetes, hypertension, and 
psychosocial stress and found that by focusing on health promotion and disease 
prevention women were encouraged to make necessary changes for a healthy lifestyle. 
Lifestyle changes that encourage weight management, exercise, smoking cessation, and 
taking steps to reduce the body core temperature have all been effective in assisting with 
the management of mild VMS (Reid et al., 2009). Although there are no randomized 
controlled trials (RCTs) to support this suggestion, promotion of a healthy lifestyle has 
advantages for overall health that extends well beyond VMS relief (Reid et al., 2009). 
Women and health care providers can look holistically at improvements to health rather 
than relying so lely on pharmaceutical treatments; however, in regards to VMS, lifestyle 
changes reduce only mild symptoms. As has been stated earlier in this paper, women are 
seeking health care for bothersome VMS, so pharmacological and non-pharmacological 
therapies may play a role in the treatment of VMS. 
Hormone therapy. 
Over the past 20 to 30 years, fluctuating expert and public opinion has been 
expressed about the efficacy and safety of HT (Huston, et al., 2009). In the 1990s, a 
notion existed that a regime of post-menopausal hmmone replacement of estrogen, with 
the addition of progesterone for women who retained their uteruses, would reduce the 
risk of heart disease (Todd Pace, 2006) . At the time, the discourse in health literature 
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shifted from HT for menopause symptom relief toward HT for prevention of chronic 
diseases (Sveinsdottir & Olafsson, 2006). Two trials, the Heart and Estrogen/Progestin 
Replacement Study (HERS), and the WHI study were conducted in the 1990s to establish 
the effects of HT on the primary prevention of heart disease (Furniss, 2002; Rolnick, 
Jackson, Kopher & Defor, 2007; Todd Pace, 2006). The primary objective of the HERS 
study was to determine whether or not hormone replacement decreased cardiovascular 
disease in post-menopausal women with known cardiac disease or breast cancer (Todd 
Pace, 2006). The results indicated that HT did not provide cardio protection and that it 
should not be used for this purpose. 
The WHI study, designed as a prevention study for women without cardiac 
disease, found unexpected results. The estrogen/progestin (EPT) arm of the study was 
stopped early due to the increased incidence of breast cancer in study participants. The 
estrogen (ET) ann of the study was also stopped early due to the increased incidence of 
stroke (Canderelli et al., 2007; Nelson, 2004). The women enrolled in the WHI trial were 
already menopausal with an average age of 63 years, and HT was used as a trial to assess 
cardio protection and not for VMS relief (Furniss, 2002; Nelson, 2004). It should also be 
noted that the strength of therapy used was 0.625mg of conjugated equine estrogen (CEE) 
alone or with 2.5 mg medroxyprogesterone acetate (MPA) (AACE, 2006). The WHI 
study therefore shed new light on the use ofHT. Now, estrogen safety warnings must be 
placed on all HT product labels and HT is only indicated for the treatment of VMS 
(Nelson, 2004). These recent studies highlight the need for practitioners to remain current 
in examining new literature. 
It was discussed earlier that risks ofHT scared women and providers alike and 
prescriptions for HT fell as a result. Results of the WHI trial revealed an increased risk of 
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breast cancer in women who used HT; however, the women enrolled in the study were on 
average 12 years post menopausal (Langer, 2009). The findings of the trial are not 
necessarily generalizable to a younger population, but fears of adverse effects remain 
(Dehn, 2007). Breast cancer is a major concern for women and the evidence suggests that 
increased rates are positively correlated with the duration of time a woman uses HT 
(Langer, 2009). The metabolic changes that occur as a result of taking HT may influence 
the incidence of venous thromboembolism (VTE) (Stevenson, 2009). Estrogen affects 
coagulation and fibrinolysis and there is a complex hemostasis effect. Simply stated, oral 
estrogen appears to increase coagulation activation resulting in VTE. In addition to the 
acquired risk of VTE when taking HT, 3% to 8% of the Caucasian population in the 
world carry a Leiden factor V gene mutation that contributes to hypercoagulation which 
results in the development ofVTE (Dee Park, Lookinland, Beckstrand & Chasson, 2003). 
In the literature review conducted by Dee Park eta!. (2003), it was found that women 
who were can·iers of the Lei den factor V gene mutation and taking HT were between 14 
to 16 times more likely to develop VTE compared to women without the Leiden factor V 
gene mutation. Women fear the adverse reactions to HT, which has created a ripe 
situation for the use of alternatives. 
Complementary and alternative medicine. 
Since the results of the WHI trial and increased fear of adverse effects ofHT, 
there has been a greater push to identify alternatives to HT for the treatment of VMS 
(Todd Pace, 2006; Wong, Dom, Luo, & Wong, 2009). Complementary and alternative 
medicines (CAMs) include various herbal products such as black cohosh or 
phytoestrogens. These particular CAMs were examined as they are the most thoroughly 
studied herbs for VMS treatment (Borrelli & Ernst, 2008; Hickey, Davis & Sturdee, 
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2005), and due to the limits of this paper, only these two supplements will be discussed. 
In 2004, the Canadian government passed legislation placing natural herbal products into 
a special drug category (Reid et al., 2009). Health Canada also introduced the Natural 
Health Products Regulation that requires products to be licensed before being sold in 
Canada (Armitage et al., 2007). Once safety and effectiveness has been assessed and 
approved by Health Canada, a product licence is issued (Health Canada, 201 0). Reid et 
al. (2009) felt that little had been achieved in the actual regulation of natural herbal 
products sold in Canada. However, a web search of Health Canada's natural health 
products site revealed licensed products sold in Canada and this includes all licensed 
herbal supplements (Health Canada, 201 0). Therefore in Canada herbal supplements that 
have been proven to be safe and effective are licensed for use. 
Phytoestrogens are the most common herbal alternative to HT (Lethaby, 2009). 
They are derived from plant compounds found in many fruits, vegetables, and grains. 
Phytoestrogens resemble estradiol and have weak estrogenic activity. Soy is one of the 
most estrogenically potent and extensively studied classes of phytoestrogens (Jacobs, 
Wegewitz, Sommerfeld, Grossklaus, & Lampen, 2009). A substance, equol, is produced 
by the intestinal flora and it is believed that it enhances the effect of the phytoestrogens. 
Only 30% to 50% ofwomen are assumed to be equol producers, thus the phytoestrogens 
are not equally effective in all women for the treatment of VMS. In the study by Jacobs et 
al. (2009), the authors concluded that additional research is needed to establish whether 
or not the action of phytoestrogens are actually influenced by equol. 
Another plant, black cohosh (Cimicifitga racemosa), has been studied extensively 
(Borrelli & Ernest, 2008). Extracts of the plant's rhizome have been traditionally used for 
a variety of female complaints such as dysmenorrhea and is thought to be mildly 
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estrogenic (Borrelli & Ernst, 2008). Other authors however, argue that the mechanism of 
action is not estrogenic, but rather it has serotonergic activity (Geller, Shulman, van 
Breemen, Banuvar, Zhou, Epstein et al., 2009). Serotonergic activity is complex, but an 
increase in activity would be effective in ameliorating symptoms of depression and 
anxiety as well as hot flashes (Hirsch & Birnbaum, 2010; Nelson et al., 2006). It is 
therefore postulated that replacement of SSRis or SNRis may be effective in reducing 
VMS (Nelson et al., 2006). 
Non-hormonal therapies. 
Non-honnonal therapies to relieve VMS include medications such as selective 
serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors 
(SNRI) which are antidepressants (Wong et al., 2009). The precise mechanism of action 
for these drugs in reducing VMS is not known, but one thought is that increasing 
serotonin levels will decrease leuteinizing hormone which will in tum reduce the severity 
of VMS (Wong et al, 2009). It is also postulated that estrogen may alter the activity of the 
noradrenergic and serotonergic system resulting in instability of serotonin and 
norepinephrine affecting the regulation of temperature homeostasis in the hypothalamus 
(Rapkin, 2007). The list for other non-honnonal medications is by no means complete but 
due to project word limit restrictions, it was elected only to discuss select antidepressants. 
CHAPTER TWO 
Literature Review 
For a health care provider, the health care encounter with peri- and menopausal 
women is challenging. Incorporating a patient-centered approach into this encounter will 
enable to provider to create a trusting relationship, identifying the patient's individual 
21 
needs and goals, offer a discussion of factual information, and involve the patient in 
mutual decision-making for a management plan. A literature review was conducted to 
answer the question pertaining to whether or not NPs can improve the QOL for women 
experiencing VMS of menopause through the use of PCC. To answer this question three 
areas of inquiry were explored: l) to discover whether PCC will improve the QOL of 
peri- and menopausal women, in tenns of the information they can obtain and the type of 
encounter they may be expecting for the treatment of VMS; 2) to determine the strengths 
ofNPs as primary care providers in implementing holistic PCC for women experiencing 
VMS; and 3) to identify the most cmTent information regarding treatment of VMS, 
including lifestyle, HT, CAMs, and non-hormonal therapy. 
Inclusion criteria 
To help keep the search strategy focused on the purpose of the paper, the 
following inclusion criteria was used: 
• Journal articles published between 1998 and 20 10; 
• Studies conducted in Canada, the US, the UK, Australia, or European countries; 
and 
• Studies that address at least one of the following topics: 
o Menopause, menopausal symptoms, including vasomotor symptoms; 
o Quality of life for women experiencing VMS 
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• 
what perimenopausal or menopausal women expect from their 
health care providers in regards to menopause; 
are the needs of women changing in terms of their health care; 
o Patient-centered care 
o Nurse practitioners; and 
o Most current evidence-based information regarding HT and CAM, 
especially in regards to black cohosh and soy and non-hormonal therapy 
including selected SSRis and SNRis. 
Exclusion criteria 
The exclusion criteria also helped to narrow down the most current studies available: 
• Studies before 1999; or 
• Articles published as commentaries or editorials. 
Search strategy 
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The databases ofCINAHL, MEDLINE -Ebsco, Alt Health Watch, PsyciNFO, and 
Cochrane Reviews were searched for the purposes of this project. W ebsi tes on the 
intemet were browsed for professional associations, guidelines and statistics. Saturation 
was felt to be reached when duplicates of articles were found in multiple databases, very 
few new articles were located and when reference lists were reviewed and some of the 
same articles were found. A manual search of the 2009-2010 submissions to The Nurse 
Practitioners Journal was undertaken where titles were reviewed to discover studies 
pertinent to the subject at hand. 
Searching the data bases required using its own language or control vocabulary or 
thesaurus (Melnyk & Fineout-Overholt, 2005) . Medline was searched using MeSH 
headings, which are the National Library of Medicine's thesaurus for MEDLINE's 
controlled vocabulary and allow a visual display of related te1ms (Melnyk & Fineout-
Overholt, 2005). [n the database Cinahl, ClNAHL Headings were used; Alt HealthWatch 
required key words or subject and PsyciN FO had its own thesaurus. Key words included: 
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• Menopause 
• Peri menopause 
• Hot flashes 
• Patient-centered care 
• Nurse practitioner 
• Hormone therapy 
• Complementary alternative medicine 
• Non-honnonal therapy 
• Quality of life 
These key words were used as concepts in reference to the question. The key word was 
entered and subheadings related to the key word were found. Applicable subheadings 
were checked and the database was then searched. Then by combining database searches 
with and a more manageable number of articles pertaining to the question were found. 
An example of the search strategy for patient-centered care produced varying 
results. fn Psycinfo and Alt Health Watch there were no results for the search term 
patient-centered care. No further search of these databases took place for PCC. Under 
Medline and Cinahl the following search tenns were used 1) PCC; 2) NP; 3) menopause 
and 4) hot flashes. 
Under Medline, the MeSH tetm menopause produced 20,800 results. The term 
menopause was broadened under a hierarchical thesaurus that retumed specific headings 
of peri menopause, postmenopause or premenopause. These subject headings were 
included and over 39,000 results were obtained. This method was done on each tem1. 
Once the main search was completed, a process of combining the terms occmTed. Under 
Medline combining PCC and NP, with a date limiter of the years 1999-2010, 76 articles 
were found. This was a manageable search and the titles of the articles were read. If the 
title contained reference specifically to women, NP or PCC, the abstract was read. This 
search resulted in 4 articles that were of interest. 
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Cinahl uses CINAHL Headmgs as its vocabulary. A subject search of PCC 
resulted in over 6,900 results. None of the key terms were exploded because it was felt 
that once key tenns were combined the results would be manageable. The Cinahl 
database resulted in seven articles of which one was the same as in the Medline search so 
total of 10 articles were obtained. Of these articles 6 were used in the paper. This in depth 
process was repeated for the other key terms indicated above. In addition, the internet 
was searched for clinical practice guidelines from Canada and the USA and those were 
reviewed with 2 guidelines selected. 
Findings 
The intended findings of this literature review are to discover whether the NP, 
when incorporating PCC for the management and treatment of women experiencing 
VMS, improves peri- and menopausal women's QOL. The need was revealed earlier in 
the paper which showed a potential for thousands of women in the province of BC 
seeking care for their bothersome VMS. Within that health care encounter, there are 
expectations that the patient will have of her provider as well as expectations that the 
provider will have of the patient. These findings will illustrate that PCC involves shared 
decision-making and reveals how women respond to PCC. Furthermore, the findings will 
demonstrate how PCC focuses on individualization of women resulting in mutually 
agreed upon treatment plans that will improve the QOL of women suffering from VMS. 
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Quality of Life 
Health care is important to women. Today many women are challenging the 
dominant medical model (Morris & Symonds, 2004) and are no longer willing to blindly 
accept a prescription, fill it, and return for a refill (Guimond et al., 2003; Legare, Stacey, 
Dodin, O'Connor, Richer, et al., 2007). A study conducted in a Canadian province found 
that women between 41 and 66 years of age conveyed a strong desire to participate in 
their own health care decisions (Armitage et al., 2007), with 59.4% of women in another 
study reported sought health care for menopausal concerns (Williams, Kalilani, 
DiBenedetti, Zhou, Fehnel & Clark, 2007). From these numbers 46.2% of women 
seeking help came out of the 40 to 44 year age group which increased to 59.6% in the 45-
50 year age group. Health-seeking for menopausal women in this study include a variety 
of complaints ofwhich hot flashes (19.3%) and night sweat (15.0%) were the chief 
complaints (Williams et al., 2007). When this same group of women were asked their 
primary reason for seeking treatment, it was for hot flashes (21.9%). A survey of hospital 
inpatients found that 75% of the patients wanted more involvement in decision-making 
for minor illnesses compared to major illnesses, and patients between 45 and 60 years of 
age wanted more participation in decision-making compared to those who were under 30 
years of age (Doherty & Doherty, 2005). For menopausal women, the desire for 
involvement stems from a need to have their perimenopausal and menopausal experience 
validated as a normal transition, and to decrease their anxiety regarding the symptoms 
they experience, thus improving QOL (Armitage et al. , 2007). These numbers alert 
practitioners to the need for patient centeredness that involves shared decision-making to 
improve health outcomes. 
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In a qualitative study by Morris and Symonds (2004), it was found that the 
menopausal time is an added stress to an already full life which negatively affects 
women's QOL; 'I've now got a big fan in the office and I have it facing me ... '(p.319). 
Similar sentiments were echoed throughout this rich infom1ative study and women of this 
study found that their QOL suffered in their home lives as well as working lives. Women 
are therefore demanding more of their health care encounter and of their health care 
provider. They want to discuss their concems, be involved in decision-making regarding 
these concems and will then be able to collaborate perceptively on their management 
plans. It is through a process ofPCC that a woman's QOL can be improved 
Patient-centered care 
A PCC approach takes into account the patient having a voice in shared decision-
making, the practitioners' understanding of their patient's desire for infonnation, 
practitioners' strong scientific and experiential knowledge and ultimately coming to a 
mutually decided plan. In literature, there are different terms that describe the 
characteristics of patient centeredness. Lauver, Worawong and Olsen (2008) use the tenn 
patient-centered interventions to describe care based on" ... clinical status, beliefs, values, 
goals or preferences" (p. 145). Another term used in the literature is collaborative 
clinical decision-making that looks beyond the biophysical approach, to an approach 
where the clinician is aware of patients individual needs, cultural background and social 
role in decision-making (Trede & Higgs, 2003). Charlton, Dearing, Berry & Johnson 
(2008) describe a tenn biopsychosocial that includes actively engaging the patient in 
discussions and decision-making regarding their own care. A model of sustained 
partnership leads to optimal care outcomes for NPs in primary care that is characterized 
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by trust and mutuality (Dontje, Corser, Kreulen & Teitelman, 2004). Despite the title of 
the approach, two components emerge as fonning the essence ofPCC: 1) patient 
participation; and 2) individualization of care (Sidani, 2008). Patient participation in 
decision making, encouraged by the NP, increases NP understanding of the needs of the 
patients in context of the patient's own values and attitudes (Dontje et al., 2004) with the 
goal of improving health outcomes (Charlton et al., 2008). 
By incorporating PCC, the NP can assist patients in health promotion and to 
formulate health goals to meet their needs. Patients in one study considered the visit to be 
patient-centered when there was discussion of the problem as well as discussion and 
agreement related to treatment options (Stewart, 2002). NPs may think that they are 
practicing in a holistic patient-centered manner, but a study conducted by Sidani (2008) 
found that patients perceived having participation in their care only to a moderate extent. 
This study was conducted on hospital inpatients and may not be generalizable to the 
menopausal population, but it alerts NPs to the possibility that their goals compared to 
patient goals may not be met. In another study, it was found that primary care patients 
who perceived their visit to be patient-centered received fewer diagnostic tests (Stewart, 
2000). The proportion of patients receiving diagnostic tests rose from 4.1% to 25.4% in 
those who perceived that the doctor and their selves had not come to a common 
understanding. These studies provide insight into how health care professionals are 
perceived by the patient even when the NP or health care provider considers they are 
delivering patient-centered care. 
Patient participation. 
A component at the core of PCC is patient participation in decision-making. 
Decision-making is not a static process and it changes in response to information 
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received. By promoting shared decision-making health, outcomes will be met more 
consistently (Dontje et al., 2004). According to a study by Legare et al. (2007), it was 
found that women want to have an active role in decision-making during menopause. 
Many women also desire the ability to collaborate with their health care provider who can 
act as a trusted source of information. Women who took an active role in their primary 
care visits had a greater reduction in health concerns, improvement in their medical 
problems and an increase in perceived control. Being actively involved in the decision-
making process was associated with increased adherence to prescribed medications 
(Salkovskis, Wroe, & Rees, 2004). Thus it appears that women rely on the NP for 
increasing their knowledge so an informed decision can be made. 
PCC encourages participation in decision-making to improve patient satisfaction 
and to attain that satisfaction education of the patient must occur. The strength of PCC 
with its connection to education makes it a strong concept to be utilized by NPs in their 
care of menopausal women. Education of the patient was an important goal identified in 
different studies (Koeniger-Donohue, 2007; Lauver eta!., 2008; Sidani, 2008). Education 
facilitates greater empowerment in patients to help them become effective promoters of 
their own health (Dontje et al., 2004). NPs that provide care in women's health appear to 
value the building of client relationships at the same time as providing a wide range of 
resources which fit the needs of the patient (Koeniger-Donohue, 2007). The value of 
building relationships was conoborated in a study by Lauver et al. (2008). Lauver et al. 
(2008) studied patients from primary care clinics and results revealed that the NP helped 
patients to attain their goals by providing health-related information. Improvements in 
health outcomes have been obtained by presenting patients with evidence-based 
information (Armitage et al., 2007). However, other types of information that may be 
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valuable to some women should not be ignored. Sveinsdottir and Olafsson (2006) found 
that women had more negative impressions about HT when they received information 
from friends and family. Armitage et al. (2007) however, found that second-hand 
information, or 'soft' information was readily accepted by the women they studied but 
the women did place their trust in the expeti advice offered by health care professionals. 
Most women have access to various types of information regarding VMS and 
treatment options; however, the diversity of such information can often give rise to 
confusion (Armitage et al., 2007). There is an immense amount of information available 
and women may find this to be less than satisfactory as the infonnation is not always easy 
to interpret (Armitage et al., 2007). This conclusion was echoed by Legare et al. (2007) 
who found that the internet provides a vast amount of information, but many women 
struggle to validate the claims and accuracy of the information. Women felt that the 
information they found in posters and booklets was being thinly disguised as 
advertisements for HT or sales promotions (Morris & Symonds, 2004). The various 
sources of infonnation seem to play a role in women's attitudes toward menopause and 
treatments. In most cases the sources of information are unsatisfactory, confusing and of 
unverified accuracy thus increasing the need for NPs to remain current with the latest 
research findings . Therefore, through the practitioner dissemination of evidence-based 
information to women, along with consideration of second hand infom1ation and also by 
listening to women's concerns regarding QOL, the provider can assist in the decision-
making process in health care encounters. The ultimate goal of this approach is to 
improve health outcomes for women. 
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Assessment of the menopausal woman. 
The other core component of PCC is individualizing the health care encounter 
based on patient characteristics, needs and preferences to improve health outcomes. The 
ability for clinicians to diagnose and determine the best treatment option for VMS relief 
is facilitated through a thorough individualized patient assessment. Individualizing the 
health care encounter has been mentioned consistently in the literature (Alexander & 
Moore, 2007; Dehn, 2007; Sarrel, Hess, Portman, Ravnikar & Simon 2006; Smith, 2005). 
A flowchart was developed by this writer by amalgamating the steps of a thorough 
assessment that had been recommended by different authors (Alexander & Moore, 2007; 
Dehn, 2007; Reid et al., 2009). The flowchart, which is presented in Appendix 1, 
provides a template for assessment of the menopausal woman and is intended for use by 
the NP during the health visit when a comprehensive health history is conducted with 
each patient. The comprehensive assessment will be less intense in subsequent visits. 
Symptom analysis of menopause may be effectively initiated by asking the female patient 
the question: How is menopause affecting your life? Assessment of personal risk factors 
such as stroke, cardiovascular disease, breast cancer, osteoporosis and VTE should be 
done along with a discussion of family history and risks (NAMS, 2010a). Gathering a full 
medication profile including over-the-counter medications is necessary (Dehn, 2007). A 
complete physical exam should focus on vital signs, potential cardiovascular, skeletal, 
genitourinary, and psychological risk factors and include a pelvic and rectal exam as well 
as a Pap test (Dehn, 2007). Health screening should include mammograms within the first 
12 months of starting HT. Laboratory studies should include lipids, liver enzymes and 
blood glucose testing (Alexander & Moore, 2007; Dehn, 2007). 
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Following the history taking and physical exam, an open discussion between 
patient and health care provider has often led to individualized treatments for the relief of 
VMS (Alexander & Moore, 2006). Counseling should include discussion of risks and 
benefits ofHT and alternatives with the choice of treatment based on risk factors and the 
woman's preferences. This is also a chance to uncover any misperceptions on the 
woman's part regarding menopause and treatment options. A menopause QOL 
assessment tool can help providers efficiently acquire information to form the basis for 
meaningful discussion (Smith, 2005). The menopause impact tool (MIT) was developed 
by Sarrel et al. (2006) to foster dialogue between the clinician and patient. This particular 
questionnaire was selected due to the rigor of development, but it is recognized that other 
questionnaires are in use; e.g. Utian Quality of Life Scale (NAMS, 2010b). Sarrel et al. 
(2006) felt that a questionnaire would raise patient awareness about menopause-related 
symptoms and their impact on four QOL parameters: 1) VMS; 2) sexual health; 3) 
psychological symptoms; and, 4) treatment assessment. They identified nine 
questionnaires that have been used in research to assess a woman's QOL during 
menopause. Many of the instruments were deemed inappropriate for use in the context of 
regular office visits. Seven of the scales were very long, some did not address 
menopausal symptoms, and others did not consider the impact on QOL. As no suitable 
questionnaire was found, a consensus team was formed to arrive at a questionnaire that 
would be suitable for the clinical setting. After considerable discussion about the wording 
of the questionnaire, the conclusion was to use a rating of the frequency of how 
bothersome symptoms are to women. At the time of the writing ofthe paper by Sarrel et 
al. (2006), clinical testing was being conducted to assess the validity of the tool with 
special attention given to ensure that the terms in the questionnaire would be eas ily 
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understood by patients. The timing and location of the use of the tool was also discussed 
(i.e., in the office, the waiting room, or at home) and the authors concluded that the 
developed questionnaire should be further evaluated in the clinical setting (Appendix 2). 
Patient-centered care is an effective way to ensure that the provider understands 
that patient participation and individualization within the health visit improves health 
outcomes. For the purpose of this paper, the provider ofPCC is the NP. The strength of 
the NP role is in the comprehensive psychosocial, biophysical, patient-centered and 
holistic approach that NPs utilize which is highly effective in enabling them to fully 
assess their patients. 
Nurse Practitioner 
NPs are proficient in assisting patients to pursue individual health care needs 
(Charlton et al., 2008). They tend to think beyond biomedical problem-solving and 
employ a more holistic view in providing care for individuals (Charlton et al., 2008; 
Trede & Higgs, 2003). This holistic perspective facilitates recognition of the multiple 
dimensions of the person and how each dimension impacts on the others (Tracey, 2009). 
Another aspect of holistic practice is " ... where the emphasis is on prevention of illness 
and maintenance of health" (Cattell, 1999). The holistic perspective, which is common in 
all registered nursing practice, is integrated and expanded within advanced level 
competencies that is unique to NP practice (CRNBC, 2006). Holistic practice is 
facilitated through balance in the NP search for the best scientific information to satisfy 
their patients' needs and the search for discovering what the patient wants, all the 
components of PCC. 
For NPs who practice PCC, being cun·ent on the most recent evidence-based 
research for adequate education of the patient and management of the patient's concerns 
was found to be an important element of PCC. NPs in BC have advanced education to 
critically review research literature and identify misconceptions or half-truths in 
quantitative or qualitative research studies (Cattell, 1999). The use of evidence-based 
research provides NPs with up-to-date information from well-designed quantitative or 
qualitative studies. Research-based randomized clinical trials have long been the gold 
standard for obtaining evidence used in making clinical decisions (Melnyk & Fineout-
Overholt, 2004). More recently, a paradigm shift has occurred so that comprehensive, 
evidence-based decision-making is used in addition to clinical experience and patient 
preferences. By combining both types of research, NPs can practice to an optimal level. 
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The education requirements in BC is a master's level which is a high attainment 
compared to NP education world wide. In a survey of 23 countries that employ NPs, it 
was found that 50% of those countries required a master's degree level of education 
(Pulcini, Jelic, Gul & Yen Loke, 2010). NPs must continuously review the literature to 
remain current in their knowledge, not only for menopausal treatments, but for every 
aspect of their patients' care (Furness, 2002). The World Health Organization (WHO) 
advocates for all health care professionals to have the professional responsibility to invest 
in continuing education (CE) in order to remain current and informed (WHO, 2010). CE 
is not unique to Canada, as the majority of countries who employ NPs have a requirement 
forCE for their ongoing licensure (Pulcini et al., 201 0). Worldwide, 81% of respondents 
repotied CE as a part of practice requirements (Pulcini et at., 201 0). In BC, the nursing 
regulatory body, the CRNBC, has outlined continuing competencies that require NPs to 
complete a learning plan for their professional development. The requirements include 
options such as research, being a preceptor for NP students, and taking credit courses, 
particularly those that are unique to NP practice such as diagnosing and prescribing 
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(CRNBC, 2010c). The CRNBC has identified six professional activities for licensure and 
require completion of three out of six per year. The CE requirement for licensure is 15 
contact hours of which one contact hour equals 50 minutes of education. With the 
continuing competencies that include educational hours, NPs are better able to meet the 
needs of their patients. In summary, the use of a holistic focus as well as the attainment of 
advanced education positions the NP as a strong health care provider. PCC is an optimal 
approach for use by NPs as it provides the individuality that is so necessary for the 
treatment options for women, especially those women experiencing VMS. A thorough 
assessment augmented by an assessment template and utilization of a menopause 
questionnaire can promote the disclosure of patient preferences. The next step is to 
provide a mutually agreed upon treatment plan. 
Current Treatments 
Therapies for VMS relief can be overwhelming. A full understanding of therapies 
is necessary as women place a great deal of trust in their provider for up-to-date evidence 
for treatment of their VMS. 
Lifestyle factors. 
Lifestyle was introduced in the background and the prevention of modifiable risk 
factors were stressed as a means of obtaining optimal health in women during their 
menopausal transition. It was unclear though whether lifestyle changes alleviated VMS 
and a Cochrane Review conoborated this finding (Daley, Stokes-Lampard, Mutrie & 
MacArthur, 2007). The authors indicated that there was no high quality randomized 
controlled study evidence to support exercise as a means of reducing VMS. However, 
lifestyle factors and their relationship to VMS were examined in the research titled Study 
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of Women's Health Across the Nation (SWAN) (Gold, Block, Crawford, Lachance, 
FitzGerald, Miracle et al., 2004). The results of this quantitative longitudinal multiethnic 
study demonstrated significance that the frequency of VMS were associated with passive 
smoke exposure and an increase in body mass index (BMI), but not for ethnicity and 
active smoking. Other research studies that were cited in the study by Gold et al. (2004) 
did not examine passive smoking. Other symptoms such as dietary factors including fat, 
fibre, caloric intake and alcohol consumption were reported but were not significant. 
These authors acknowledge that the associations found should be further researched in 
other longitudinal studies. Another limitation to the study conducted by Gold et al. (2004) 
was that VMS were not quantified in severity or frequency so assessing for changes with 
lifestyle interventions was difficult. 
Thurston, Sowers, Chang, Stemfeld, Gold, Johnston et al. (2007) analyzed the 
associations between adiposity and VMS. Research findings revealed that a greater 
percentage of body fat was significantly associated with an increased reporting of VMS. 
Again, VMS were not discussed in frequency or severity, just that there was a positive 
conelation between adiposity and VMS. These authors suggest that further study is 
needed to determine whether or not weight loss has any impact on VMS. These examples 
are only a small representation of the analysis of the influence of lifestyle factors on 
VMS and are by no means complete. They do however demonstrate the complexity of 
menopause transition and the necessity for ongoing research in this area. The ability for 
intended lifestyle changes, while important to over all health, appears to do little in 
alleviating VMS in most women. Therefore medication should be discussed and offered 
to women based on its efficacy and consideration of a patient's individual risk/benefit 
assessment. 
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Hormone therapy. 
The North American Menopause Society (NAMS) and SOGC develop clinical 
practice guidelines (CPG) and, according to these societies, hormone therapy is the most 
effective treatment for VMS and is indicated for use in the presence of moderate to 
severe VMS (NAMS, 2010a; Reid et al, 2009). CPGs are "statements that have been 
systematically developed to assist practitioners and patients in making decisions about 
care" (Melnyk & Fineout-Overholt, 2005, p. 209). CPGs can assist in bridging the gap 
between published scientific evidence and clinical decision-making (Melnyk & Fineout-
Overholt, 2005). Cun·ent evidence indicates that HT is the best treatment for reducing hot 
flashes, compared to the effect of placebo, or any CAM or non-hormonal treatment 
cun·ently available (NAMS, 2010; Reid et al., 2009). HT has been well studied and 
continued studies of its efficacy for the relief of VMS are unwarranted (MacLennan et al. , 
2004). HT reduces VMS in perimenopausal women by 65% and in menopausal women 
by 90% compared to a placebo (Alexander & Moore, 2007; Hickey, et al., 2007). 
Conventional HT consists of estrogen replacement with the addition of progestin for 
those who retain their uterus (Langer, 2009). The goal in prescribing HT is to determine 
the lowest dose that effectively alleviates bothersome perimenopausal and menopausal 
VMS (Langer, 2009). 
A study by Mattsson, Skouby, Rees, Heikkinen, Kudela, Stadnicki-Kolendo et al. 
(2007) evaluated estradiol valerate (E2V) with medroxyprogesterone acetate (MPA) in 
preparations of 1:2.5 mg or 1:5 mg as low doses and 2:5mg as high dose. The actual dose 
is dependent upon the individualized response of the woman and susceptibility to side 
effects, such as breast tenderness or break-through bleeding. Oral low dose therapy 
showed a similar reduction in the number of hot flashes at the 12 week period of therapy 
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compared to higher doses. The reduction in number of flashes per week fell from greater 
than 30 to less than 5 in 12 weeks. At 40 weeks, the VMS were reduced by 69.9% in the 
1:2.5 mg group, 63.1% in the 1:5mg group and 77.3% ofwomen in the 2:5mg group and 
in fact these women were considered free ofVMS. CEE and oral and transdermal 17B-
estradiol were more effective than placebo in relieving VMS, however, studies do not 
support the efficacy of one type of estrogen over another. HT is effective for relief of 
VMS but also comes with adverse effects. 
Another group of authors reported on QOL outcomes using the three doses 
described in the Mattsson et al. trial (Pitkin, Petrovna, Smetnik, Vadasz, Mustonen, 
Salminen et al., 2007). They studied effects ofHT on climacteric symptoms such as 
mood, memory/concentration, anxiety/fears, sleep problems, somatic symptoms, 
menstrual symptoms, attractiveness and sexual behavior as well as VMS. They found that 
at baseline the women enrolled in this Finnish study that had experienced >30 VMS/week 
had lower QOL scores compared to age-matched women with no complaints. The results 
demonstrated a significant improvement in climacteric symptoms, in all treatment groups 
at week 52 (?<0.0001). This analysis of a recent randomized control trial demonstrates 
that HT relieves VMS resulting in an improved QOL. 
HT is not without risks. The most commonly reported adverse effects ofHT are 
atypical bleeding, breast tendemess, weight changes, venous thromboembolic effect and 
related cardiovascular problems (Nelson, 2004). Mattsson et al. (2007) compared three 
different strengths of estrogen and progesterone and there were 244 recorded adverse 
events related to drug therapy. Examples of adverse effects were bleeding/spotting, breast 
tenderness, uterine fibroids, or nausea. The number of events were statistically significant 
(?=0.0002) with more adverse events in the higher dose combined therapy group versus 
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the two other groups. Major adverse effects were rarely observed in 32 RCTs synthesised 
by Nelson (2004). Two reports of deep vein thrombosis were reported in women using 
CEE, and two cases of endometrial cancer with E2. All other adverse effects, for example 
breast tenderness, were felt to be nuisance in nature and not considered statistically 
significant. Major side effects of bleeding/spotting or breast tenderness that caused 
premature withdrawal in the study conducted by Mattsson et al. (2007), occurred in 23 of 
458 women. The most serious side effect was uterine bleeding/spotting. There were five 
bleeding events, or 3.5% of the study population, but only one (0.7%) was considered to 
be drug related. 
The SOGC and NAMS CPGs suggest that breast cancer is not increased with the 
use ofHT for a limited time period, but it can be increased by approximately 2% per year 
after 5 years ofuse (NAMS, 2010a; Reid et al., 2009). The risk of breast cancer with 
appropriate HT treatment is put into perspective with a comparative risk that is similar to 
that of women who experience early menarche, late menopause, did not breastfeed, or 
had their first pregnancy after age 30. The SOGC guidelines also indicate that the risk for 
women with 1 st degree relatives with breast cancer is slightly increased compared to the 
12% risk seen in the general population (Reid et al., 2009). That risk rises to 24% when 
the 1st degree relative had breast cancer before the age of 50 years, and 48% with 2 
relatives. As for those women who are breast cancer survivors, there is no definitive 
evidence as to whether or not HT will influence further breast cancer risk. 
Another risk factor associated with HT use is VTE, which usually occurs within 
the first one to two years ofuse (NAMS, 2010a). VTE occurs more frequently in women 
who use combination estrogen progestin therapy. The risk of VTE increases in 
overweight women with a hazard ratio (HR) of 1.96%, obese women whose HR tripled to 
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3.09%, and among those with the Leiden factor V gene mutation in which a HR was not 
given (Reid et a!., 2009). A hazard ratio is a measure of how often a particular event 
happens in one group compared to how often it happens in another group (National 
Cancer Institute Dictionary, n.d.). In a literature review conducted by Dee Park et al. 
(2003 ), it was found that women who were carriers of the Lei den factor V mutation and 
taking HT were between 14 to 16 times more likely to develop a VTE compared to 
women without the factor. In the WHI trial, the HR ratio was 4.0 in the first year ofHT 
and fell to 1.04 by year six. The risk is doubled for women who are 50 years old and 
taking HT, however the greatest risk for VTE occurs among women older than 60 years 
and using HT (Reid et al., 2009). Health care providers must be aware of any 
contraindications to the therapy they choose. The contraindications to estrogen use are: 1) 
unexplained vaginal bleeding; 2) acute liver disease; and, 3) active thromboembolic 
disease. Contraindications of progesterone therapy are: 1) known or suspected carcinoma 
of the breast; 2) undiagnosed vaginal bleeding; and, 3) pregnancy (Rowe et al., 2006). It 
is impmiant to counsel women on adverse events but equally important to be aware of the 
duration of treatment for optimal health. 
Duration of HT treatment is crucial since it determines the length of time that a 
woman should receive VMS treatment, but uncertainty exists. The shortest time frame is 
not firmly established and for most women the duration of VMS is distinct and individual 
(NAMS, 2010a; Politi et al., 2008; Reid et al., 2009). According to Col et al. (2009), no 
studies conducted to date have lasted long enough to capture the true length of 
menopausal VMS. Their findings suggest that the mean duration of bothersome hot 
flashes was 5.5 years (range from l to 13 years). No significant differences in hot flash 
duration were found by comparing HT users to never-users . The authors suggested that to 
be accurate, a longitudinal analysis of the duration ofVMS should begin at the 
commencement of symptoms until they terminate (Col et al., 2009). 
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Knowing the optimal time when symptoms are at their worst is crucial. Studies 
have shown that VMS increase in the years before the final menstrual period, peak in the 
first year after the final menstrual period, and slowly wane over an approximate eight 
year period (Politi et al., 2008). This time frame has been corroborated in another study 
that showed the prevalence of hot flashes increasing as women approached menopause, 
from 13% in early perimenopause transition to 79% in the early menopausal stage 
(Lewis, 2009). Clinical implications of this time frame are significant, as a longer 
duration of symptoms may alter treatment decisions and clinical practice. The SOGC 
CPG suggests that HT should be not be used for more than five years to treat VMS, but 
longer courses of treatment may be considered for women who have prolonged VMS in 
discussion with their health care provider and on an individual basis (Reid et al., 2009). 
Since the duration of VMS vary among women, an individual woman's risk-benefit 
profile must be conducted if HT is to be used for more than five years. Women should be 
counseled that their risk of breast cancer may rise if they are taking a combination of 
estrogen and progestin (Col et al., 2009). This infonnation impacts on the duration of 
therapy and understanding this will facilitate the patients ' ability to make informed 
decisions regarding treatment (Col et al., 2009). Treatment options must be weighed 
carefully and consideration for discontinuation needs to occur, though questions remain 
regarding how to discontinue E-IT. 
Despite the fact that studies suggest HT should be used for as short a time as 
possible, there is disagreement on when and how to di scontinue HT (Pinkerton et al., 
2009). For most women, VMS will subside and stop over time, but up to 25% of women 
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will be unwilling to stop HT due to persistent VMS (Pinkerton et al., 2009). A study 
aimed at examining the tapering down or abrupt discontinuation of HT was conducted by 
Lindh-Astrand, Bixo, Hirschberg, Sundstrom-Poromaa and Hammer (2010). To 
determine the impact of discontinuation, resumption of hot flashes was the primary study 
outcome with a QOL assessment as a secondary outcome. Results concluded that there 
were no statistical differences between the two study groups (P=0.85). Quality of life 
was assessed with a Psychological General Well-Being Index (PGWB) which included 
questions related to general health, anxiety, depression, vitality, self-control and well-
being. The PGWB assessed QOL at baseline and at 6 weeks after discontinuation of HT 
with a score of 0 indicting the most negative option and 5 indicating the most positive 
option. Results found that those women who had resumed HT had a significantly more 
pronounced decrease in PGWB score in all categories compared to those who did not 
resume HT (P<O.OO 1 ), with the most impotiant single indicator being the severity of hot 
flashes. Thus, there is no agreement on how to discontinue HT and whether a "cold 
turkey" approach or a gradual reduction in dose over time is more appropriate (Hickey et 
al., 2005 ; Lindh-Astrand et a l. , 2010; NAMS, 2010a; Pinkerton et al. , 2009). Not all 
characteristics of the population were measured such as body mass index or exercise and 
Lindh-Astrand et al. (20 l 0) conclude that results may have been different if other specific 
population characteristics had been used. This is impotiant information for NPs to have 
and to advise their patients of when considering tailored care for women discontinuing 
HT. 
Complementary and alternative medicine. 
Some women will be unwilling to initiate HT. Whether it is due to personal 
preference or uncertainties about adverse effects and benefits of HT, many women seek 
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altematives for relief of VMS (Borrelli & Emst, 2008; Geller et al., 2009; Jacobs et al., 
2009; Lethaby et al. , 2009). Whatever the reason, it is important for NPs to have 
appropriate knowledge about all treatment options available for VMS relief. Many CAMs 
have become popular since the results of the WHI trial were made available, including 
herbal supplements such as black cohosh and phyto-estrogens (Geller et al. , 2009). 
Evidence indicates that up to 62% of women believe that "natural" plant-based hormones 
are at least as effective as HT in controlling VMS (Jacobs et al., 2009; Lethaby et al., 
2009). Despite this large popularity, caution needs to be taken with consideration ofusing 
supplements. 
Consumers and health care providers should exercise caution when using or 
recommending CAM and be aware of the actual strength and consistency of available 
products (Armitage et al., 2007; Reid et al., 2009). Difficulty in comparing the efficacy of 
supplements is due to multiple strengths and differences in the compounding of products 
(Borrelli & Emst, 2008; Jacobs et al., 2009; Lethaby et al., 2007). Exact comparisons and 
conclusions about efficacy are problematic when the strength of a given product cannot 
be extrapolated to other products in the same class. Researchers have described difficulty 
in comparing results, for example in the comparison of black cohosh and phyto-
estrogens, due to differences in herbal preparations (Borrelli & Emst, 2008; Jacobs, et al., 
2009; Lethaby et al., 2007). Becoming aware of the difficulty of comparing the different 
manufactured products makes the prescribing of herbal supplements challenging. 
Black cohosh, an herbal supplement, was the seventh top-selling herbal 
supplement in the US in 2007 (Teschke, 201 0). Studies have been inconclusive to its 
effectiveness in reducing the frequency or intensity of VMS among peri- and menopausal 
women. Borrelli and Ernst (2008) performed a systematic review and results of data 
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suggest that black cohosh can reduce the intensity but not the frequency of VMS; 
however, the evidence is insufficient to conclude that black cohosh can effectively 
control VMS. This finding was also reported by Geller et al. (2009) who found that black 
cohosh was no better than placebo and was actually less effective in reducing VMS (35% 
versus 63%). There were no statistically significant differences in the number or intensity 
of VMS between the black cohosh group and the placebo group except at the sixth and 
ninth month of intervention which at that time the black cohosh group showed greater 
symptom intensity compared to placebo. Many women continue using the supplement 
despite its poorly reported perf01mance in reducing VMS. Geller et al. (2009) noted that 
black cohosh did not produce adverse effects and was safe in terms of breast tissue, 
endometrial thickness, liver enzymes, complete blood counts and lipid profiles; but, the 
authors could not comment on any adverse events when black cohosh was coupled with 
drug and or alcohol use. This is important information for health care practitioners when 
personalizing the care of women. 
Another widely studied class of supplements are the phyto-estrogens with three 
main classes including isoflavones, lignans, and coumestans (Jacobs et al., 2009). The 
plant-based substance binds to estrogen receptors and exe1is various estrogenic or anti-
estrogen effects (Jacobs et al. , 2009). The most extensively studied class ofphyto-
estrogens is isoflavone, which occurs largely from soybean. Wong et al. (2009) 
conducted a literature review of CAM used in menopause. They found that trials lasting 
longer than six weeks demonstrated statisticall y significant improvement in the reduction 
of VMS with one longer study of 24 weeks duration showing no overall difference. One 
can argue that the placebo effect, which is reported to be as strong as 58% in women, 
could account for the improvement in VMS and is not necessarily attributable to the 
product being tested (Lethaby, et al., 2007). 
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The Herbal Alternatives for Menopause Trial (HALT) conducted in the US was a 
one year trial to study the effects of herbal supplements that are widely used for VMS 
(Newton, Reed, LaCroix, Grothaus, Ehrlich & Guiltinan, 2006). The primary outcome 
was a reduction of VMS from baseline and at different time intervals. Within the first 
three months a decrease in VMS frequency compared to placebo was observed, but for 
the following time intervals there were no statistically significant differences observed 
with one exception. At 12 months there was a worsening of VMS in a treatment group 
taking a multibotanicals plus soy product. Lethaby et al. (2007) conducted a systematic 
review and came across similar findings with the majority of studies reporting the effects 
of interventions with no significant differences between the soy and the placebo control 
group. While herbal supplements may be popular, there is insufficient evidence to 
support their effectiveness beyond a placebo effect. 
Non-hormonal therapy. 
A class of drugs that has been evaluated for treatment of VMS includes the SSRI 
and SNRI antidepressants. Citalopram is an SSRI that was trialed for effectiveness for 
controlling VMS when the drug venlafaxine, a SNRI, failed to achieve VMS control 
(Loprinzi, Flynn, Carpenter, Atherton, Barton, et al., 2005). This trial was not placebo 
controlled but rather a study on whether citalopram was more effective in reducing VMS 
than venlafaxine. Results found that citalopram reduced hot flashes by 53% therefore 
revealing positive results were found with this SSRI. In a placebo-controlled prospective 
trial, two SSRis, citalopram and fluoxetine, were studied against a placebo (Suvanto-
Luukkonen et al., 2005). The trial had a large attrition rate which may have skewed the 
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results. At the nine month mark between 32% and 40% of the population dropped out 
mainly due to the treatment's lack of effectiveness rather than adverse side effects. In the 
remaining participants, the results demonstrated a decrease in VMS by 50% in the 
fluoxetine group, 70% in the citalopram group and 60% in the placebo group. Adverse 
effects of these drugs were headache, arthralgia, depression, dry mouth, libido problem 
and blurred vision. These adverse effects, although not life threatening, resulted in 37% 
of the study patients dropping out before completion of the study. 
A systematic review conducted by Nelson et al. (2006) revealed that with use of 
paroxetine, a SSRI, peri- and menopausal women experienced fewer hot flashes 
compared to placebo (3.3 vs 1.8 fewer, P=0.01). Other studies within this review found 
no significant differences in the frequency of VMS when using the SSRis fluoxetine or 
citalopram. Studies that reviewed venlafaxine found that it significantly reduced hot flash 
frequency compared to placebo (30%-58% vs 19%, ? <0.001), but this study was in a 
special group of women with breast cancer. A smaller study of this review found that 
there were no significant reductions in frequency of hot flashes. In this systematic review 
the most common adverse effects reported were headache, nausea, drowsiness, a decrease 
in appetite or dry mouth. Overall, the authors feel that the randomized placebo-controlled 
trials examined in their review do support the efficacy of SSRis and SNRis in reducing 
hot flashes. Women could be counseled on the positive effects SSRis and SNRI in 
treating their VMS. 
Limitations of review 
This paper provided an overview of current information regarding HT along with 
its safety and efficacy. One limitation was not making specific recommendations for 
treatment based on specific doses, routes and types of medications on the market for 
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VMS, whether they are HT, CAMs or non-hormonal therapy. Word limits and the 
specific focus of the paper limited complete discussion of all therapies available to treat 
VMS. Another limitation is the brevity with which lifestyle factors and the influence to 
VMS were discussed; however, this could be a paper unto itself. Also the literature search 
did not reveal any studies that focused on PCC and the menopausal woman. By taking 
these characteristics of PCC and applying these to the medical encounter it was shown 
that NPs using PCC can effectively assist women to manage their VMS. 
CHAPTER3 
Discussion, Implications, Recommendations and Conclusions 
Discussion 
Mild, moderate and severe VMS occurring during the menopause transition can 
be bothersome for many women causing them to seek advice and treatment from their 
health care provider. VMS are not a disease in need of a cure; they are an aspect of a 
physiological transition that can be tolerated with education and management. 
Bothersome VMS are one of the leading reasons peri- and menopausal women seek 
medical care, and it was detem1ined that thousands of women in BC seek help for VMS 
at any given time. The topic of VMS was explored in order to gain insight into the current 
existing evidence that is available to assist practitioners in providing appropriate 
management for women. The overreaching purpose of this paper was to answer the 
question, "Can NPs utilize PCC to help improve the QOL of women experiencing 
VMS?" and the answer to this question is yes. 
PCC is a general approach to personalize care to meet individual needs (Sidani, 
2008). PCC has an ultimate goal to increase patient satisfaction and to improve patients' 
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QOL. For the purposes of research projects, distinctions on the severity of VMS are 
dependent on the frequency and/or severity of the hot flashes. Those variables may be 
good data-collection points for research but do not necessarily fit a pattern that is 
reflective of women's real life experience. In real hfe, even one hot flash, in the midst of 
an important business meeting or other social event can be disturbing. Especially if you 
picture that woman standing in front of a group of people and suddenly her face is 
flushed and perspiration is forming on her upper lip. The woman quickly and 
inconspicuously, or so she thinks, sheds her outer garments only to put them back on in a 
few minutes when she now begins to feel chilled. This scenario illustrates that QOL can 
be impacted negatively with the onset of VMS. In the descriptive qualitative studies 
included in this paper women do not talk in frequency or severity they just talk about 
inconvenience and embarrassment. Therefore a NP's proficient assessment and 
commendable patient-centered skills can culminate in a collaborative management plan 
that will evoke satisfaction for the patient with the ultimate of goal of a resumption of a 
QOL that the woman who once suffered by bothersome VMS once again enjoys. 
PCC has two definitive goals that include patient participation and 
individualization. Women want to be heard and many want to be involved in the 
decision-making process when it comes to their own health care. Studies conducted on 
decision-making revealed that may women want a commanding role in the decision-
making process when it comes to menopause care. The results of these studies act as a 
reminder to NPs that women want to be actively involved in the health care encounter, 
which will assist in alleviation of fears and anxiety surrounding the menopause transition, 
but do NPs always incorporate PCC? Research showed that patients felt that it is not 
always being clone. That being said, the population of people in the studies may not be 
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generalizable to a population of primary care menopausal patients; however, these studies 
do highlight to practitioners that PCC is not always being used. Studies have also shown 
that not all patients want to be that involved in their health care decisions and so all will 
not participate in shared decision-making which leave management plans up to the 
practitioner. Based on current literature, this author has concluded that practitioners need 
to assist patients individually in managing their health as collaboratively as the patient 
wants. 
Another goal of PCC is individualization. Research has shown that women do not 
want standardized care where one-size-fits-all. The shift to individualization ensures that 
each woman's unique wants and needs are being met and the crucial exploration of the 
risks and benefits of the woman's preferred therapies can occur. NPs have prescriptive 
authority where they base their decision for medication use following a careful history, 
assessment and a thorough discussion of what the woman wants. Utilizing patient 
centeredness by listening to the woman and supporting her choices is vital to ensuring 
adherence to treatment plans. 
Once the information gathering has taken place, the advanced knowledge that 
practitioners possess enables them to aid the patient in developing a plan. A key 
component to PCC is knowledge. Women want to engage in intelligent conversations 
surrounding HT, CAMs and altemative therapies for VMS management. It was shown 
that it is difficult for women to decipher fact from advertisement and they rely heavily on 
their health care provider. For the provider, it can be equally difficult to remain ctment 
with the vast amount of research that is available. NPs, whose graduate education 
includes analysis of research, are in an optimal position to help make sense of all the 
information that is available to women. 
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Strength ofNPs as care providers lies in their ability to interact with their patients. 
The NP's unique holistic approach facilitates communication of not only best-evidence 
but devotes great importance to exploring a woman's goals regarding her health. NPs 
complete a health history and thorough assessment of each woman while creating a 
therapeutic relationship that explores women's wants and needs. A flowchart can aid in 
the organization of the health care encounter and ensure that steps are not missed (see 
Appendix A). A tool, such as a questionnaire, can be used as an introduction to the topic 
of menopause and may be a valued addition to the health assessment (see Appendix 2). 
This type of self report is a way to collect information. The NP can then work with that 
infonnation and arrive at a decision based on his or her knowledge of pharmacology and 
prescribing practices so a mutual yet safe management decision is attained. Thus a 
questionnaire can provide a foundation for a more therapeutic, satisfying relationship 
between provider and patient. When integrated NP competencies, enhanced clinical skills 
and measurement tools are considered in the context of this paper, it becomes evident that 
NPs are educated to integrate patient-centeredness into their practice and are highly 
effective practitioners and consultants for supporting women with VMS complaints. 
NPs have been introduced into BC's medical community to improve access to 
health care. By utilizing PCC as a general approach to personalize care to meet the needs 
of the individual; NPs are in a position to provide competent health care. It is not one 
certain element or competency that make NPs an optimal choice as primary health care 
provider, but rather a combination of competencies fundamental to the NP role that are 
integrated into practice. By integrating the competencies of clinical practice, research, 
leadership, health assessment, diagnosis and therapeutic management, the NP educates 
and advocates for individuals in relation to decisions that may affect their health and 
ultimately their QOL. 
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This paper contained extensive infom1ation relating to the different therapies for 
the treatment of bothersome VMS. Studies have been conducted to examine the type and 
dose of estrogen or combined estrogen/progestin that is required for efficacy. HT has 
been shown to be the most effective treatment for women experiencing bothersome 
VMS. Part of the art of prescribing is choosing an appropriate regime for individual 
women. Current recommendations for women who are considering HT are that the lowest 
effective dose of estrogen should be prescribed, with the addition of progestin for those 
with an intact uterus, to obtain VMS relief. HT should be given for duration of less than 
five years to reduce the potential for serious adverse effects. This makes it imperative that 
NPs and health care providers recognize that VMS occur most frequently in the year 
before menopause and the year or two following a woman's last menstrual cycle. This 
allows women and their practitioners to decide when to start HT for maximum efficacy 
while realizing that the duration of menopause is individual for women with some 
experiencing VMS well into their 60s. CPGs can be used by the NP to provide the most 
current information regarding HT as well CAMs or non-hormonal therapy (Reid et al., 
2009). A limitation for guideline use is that they are just guides that integrate evidence 
for practice but may not fit all situations or be generalizable to individual women. 
NPs will encounter women who will make the decision not to use HT. This 
review has found that HT is often the only treatment option provided to women by many 
health care providers, and alternatives to HT are not always discussed. NPs value shared 
decision-making with their patients and the use of PCC individualized attention and 
consideration of diverse therapies will prevent a narrow approach to VMS management. 
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CAMs are growing in popularity as alternatives to HT and women are being inundated 
with less than reliable sources of information obtained from the internet or print material 
leaving them with unanswered questions. NPs will be expected to answer these women's 
questions with the same judiciousness as when answering questions about HT. Effective 
information exchange and trust between the patient and provider can aid in selecting 
optimal treatment options (Lewis, 2009). As for adverse effects, it was shown that all the 
different hormonal and non-hormonal oral treatments come with their own list of adverse 
effects. Experience of these effects may create discussion in subsequent medical 
appointments and a patient-centered approach will help produce satisfaction with the 
health care encounter. 
Implications for Practice 
The purpose of this paper has been to discover whether the use of PCC in the 
health care encounter improves QOL for women experiencing VMS. From this 
information implications and recommendations for NP practice have become apparent. 
The competencies that define the NP role include all the components of PCC: 1) holistic 
practice that focuses on the person and encourages patient involvement; 2) advanced 
assessment skills that reveal the uniqueness of each person; and, 3) a strong scientific and 
experiential knowledge base from which to present information and develop safe and 
effective treatment options and management plans. What is known is that NPs practice to 
a high standard. Studies of women's experiences of the health care encounter NPs reveals 
that PCC can improve their QOL by incorporating it into each health visit. To address 
women's needs more completely, a comprehensive approach must be conducted. 
• NPs caring for women with VMS should incorporate a patient-centered approach 
at each visit. A full initial health history, discussion of women's goals, 
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risk/benefit assessment and development of a collaborative management plan will 
improve health outcomes and QOL. A history update is all that is required in 
subsequent visits. 
• The PCC approach is useful for new and experienced NPs as they strive for better 
understanding of the complexities of their individual patients. 
• NPs caring for women with VMS should incorporate qualitative assessment tools 
such as the MIT to improve supportive individualized care and assist the woman 
in understanding vasomotor symptoms. 
Recommendations 
The research has provided vital information that explains VMS and treatment 
options. It is recommended that NPs apply the clinical research found in this paper along 
with the use ofCPGs in the management of women experiencing VMS. The CPGs will 
guide the NP in providing the most appropriate treatment. It is also recommended that 
continuing education will assist the family NP in providing evidence-based information 
to women experiencing VMS of menopause. 
Future research. 
Nurse practitioners have advanced fmmal as well as experiential education that 
places them in an advantageous position to determine where future clinical research 
topics exist. By utilizing reflective practice NPs may come up with more significant 
topics on women's health for future research. 
• As a NP, I would like to conduct research on whether or not the effects of PCC 
have a positive impact on the QOL of women experiencing VMS. The 
components ofPCC would need to be clearly defined as well as standardizing 
measures of QOL indicators. It is hypothesized that the results would show an 
improvement of women's QOL. 
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• As a NP, I would like to further the development of an assessment tool, applying 
evidence-based research to its development and validating it in clinical practice. 
• Specialty training can lead to the development ofNP-led practice groups in 
primary health care focusing on women's health. Further research into whether 
PCC can be applied to group visits for women in menopause is warranted. 
Conclusion 
Nurse practitioners are a valuable addition to the primary health care team in 
British Columbia. This paper has discussed just one small part of the care of women, but 
it has highlighted the strength of the NPs as skilled practitioners who, along with the use 
ofPCC, can be the best providers for the care of women experiencing VMS. 
Patient-centered care is an approach that allows woman who experience VMS to 
bave a voice, share in decision-making and collaboratively agree to a treatment plan. The 
PCC approach addresses women's concerns regarding VMS that are impacting on QOL. 
The experience of VMS is unique and individual for each woman, so it is imperative for 
the NP to listen to what individual women say. This listening needs to encompass not 
only to how VMS are impacting on life, but also needs to include how each woman wants 
to proceed in regard to treatment. The NP is skilled in presenting treatment options such 
as lifestyle changes, HT, CAMs or non-hormonal therapy to women experiencing VMS. 
Employing lifestyle changes such as weight control and smoking cessation will help 
improve overall health. Specific to VMS, NPs will counsel the woman on the various 
treatment options available to them. 
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NPs provide care that is holistic and patient-centered. Their advanced knowledge, 
training and skills enables NPs to effectively assist women in the management of VMS of 
menopause by enhancing health care and improving women's quality of life. 
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Appendix 1 
Assessment of women for vasomotor 
symptom complaints 
~ 
Offer questionnaire in waiting 
room to complete or take home 
t 
History/ Assessment 
- Individualized for each patient 
-Assess for major risk factors 
i.e. breast cancer or VTE 
- Physical exam, health screening and laboratory studies 
- shared decision making regarding treatment options 
Lifestyle 
changes 
-reduce body 
core temp 
-weight 
management 
-smoking 
cessation 
Hormone therapy 
-estrogen alone or 
with progestin 
-start low and 
titrate to individual 
response 
hormonal 
therapy 
-SSRT 
-SNRI 
-others* 
Follow up and reassess women on a yearly 
* See SOGC guidelines for other non-honnonallherapies 
References 
Alexander & Moore (2007) 
Dehn (2007) 
Reid ct al. , (2009) 
CAM's 
-discuss limited 
evidence of 
benefit 
for VMS 
-lack evidence of 
efficacy 
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Appendix 2 
---------Menopause Impact Tool--------
Patient Name: ______ _ Date of Birth:__ _ ___ _ 
HilS SECTiON TO SE COMPLETED BY <~EAL THCM~E PROFESSrONAL 
Dme. _______ _ 
Patient lnstructrons: Please answer the questions below prior to meeting with your healthcare professional who will review 
the completed questior1naire during your office visit 
Rating Scale: 1- Not at all or rarely 2- A little or moderately 3- Regularly or frequently 
Assessment of Vasomotor Symptoms 
In the last month, to wh<lt extent have you been bothered by the to flowing symptoms? Please rate each symptom from 1 to 
.:1 (refer to above scale and circle yo11rresponse). Then, place an "X'' in ONE of the boxes to indicate which ONE symptom is 
most bothersome to you, or most disrupts your daffy life. 
Hot flashes 1 2 3 0 
Night sweats or chuls 
Sleep disturbance 
Joint pain or stiffness 
Fatigue 
2 
2 
2 
2 
3 
3 
3 
3 
0 
0 
0 
0 
To what extent have these symptoms negatively impacted the following (refer to above scale and circle your response)? 
Feelings about yourself 2 3 
Relationships 2 3 
'Nark 2 3 
__ Total Vasomotor Symptoms Assessment Score 
Assessment of Sexual Health . 
In the last month, to what extent have you been bothered by the following symptoms? Please rate each symptom from 1 to 
.:1 (refer to above scale and circle your response). Then , place an ''X" in ONE of the boxes to indicate which ONE S)Hllptom is 
most bothersome to you, or most disrupts your daily life. 
Genital Dryrx:ss. pain and/or burning 2 3 0 
Pain during sexual activtt:r 2 3 0 
Decreased sexual desire 2 3 D 
Decreased S•3xual response 2 3 0 
Decreased sexual frequency 2 3 D 
To what extent have these symptoms negatively impacted the following (refer to above scale and circle your response)? 
Feelings about yourself 2 3 
Relatk:Jnships 2 3 
1Nark 2 3 
Total Sexual Health Assessment Score Page 1 
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--------Menopause Impact Tool--------
Assessment of Psycho log leal Symptoms 
In the last month, to what extent have you been bothered by the following symptoms? Please rate each symptom from 1 to 
'J.(refer to above scale and circle your response). Then, place an ''X" in ONE of the boxes to indicate which ONE symptom is 
most bothersome to you, or most disrupts your daily life. 
Anxiety 2 3 D 
lrrilabitity 2 3 D 
Sadness 2 3 D 
Difficulty concentrating 2 3 0 
To what extent have these symptoms negatively impacted the following (refer to above scale and circlE! your response)? 
F oolings about yourse~ 
Rela~onships 
Work 
2 
2 
2 
.. __ Tot;ll Psychok:-gtc.1l Symntom:; Asss.ssrn!lnt Score 
3 
3 
3 
-·-·--Total Score for Menopause Symptoms and Impact Assessment (Please .1dd Total Assessment Scores from the above 
for Fin.11 Total). 
Treatment Assessment 
Pfease choose the statement that applies to yoll (Check the most appropriate response). 
___ "I'd like to try hormone therapy for the treatment or my menopausal symptoms.· 
___ _ ' I'd consider laking hormone therapy for the treatment or my menopausal symptoms, but I would first like to learn more.· 
_____ "I've taken hormone therapy in the past for 1110 treatment of my menopausal symptoms, but I didn't like it.• 
____ "I'll never take hormone therapy for the treatment or my menopausal symptoms: 
i!ffi.i>£~~1\t£JiJ; SECiiOtl fO &f. C'OMPU::TED !l'i Y()U!l N£AU!10lRE PiiOF£SS!ONM 'iiE I~•'FCR/,14111fi'<M0Vf., 'liCUJI:!'Nt. iN£ WT4t.SCORF., 
WU Sf Af141.'fl£D llY fOOR tiE ALfHCAI'F f'i<CWi:'S$1!'1/AL 
Menopause Impact Tool. Retrieved from 
http: //www.femalepatient.com/pdf/MenopauseimpactTool.pdf 
